Two Sigma Investments LP Grows Stock Holdings in Guardant Health, Inc. (NASDAQ:GH)

Two Sigma Investments LP lifted its stake in Guardant Health, Inc. (NASDAQ:GH - Free Report) by 38.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,890,714 shares of the company's stock after acquiring an additional 525,368 shares during the quarter. Two Sigma Investments LP owned 1.53% of Guardant Health worth $57,761,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. R Squared Ltd bought a new stake in shares of Guardant Health in the fourth quarter worth approximately $26,000. SBI Securities Co. Ltd. bought a new stake in shares of Guardant Health in the fourth quarter worth approximately $43,000. Kimelman & Baird LLC bought a new stake in shares of Guardant Health in the fourth quarter worth approximately $58,000. NewEdge Advisors LLC grew its stake in shares of Guardant Health by 13.5% in the fourth quarter. NewEdge Advisors LLC now owns 1,929 shares of the company's stock worth $59,000 after acquiring an additional 230 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Guardant Health in the fourth quarter worth approximately $61,000. 92.60% of the stock is currently owned by institutional investors.

Guardant Health Stock Up 2.6%

NASDAQ:GH traded up $0.95 during trading hours on Friday, hitting $38.00. 1,373,039 shares of the stock traded hands, compared to its average volume of 2,145,131. Guardant Health, Inc. has a 1 year low of $20.14 and a 1 year high of $52.92. The company has a market cap of $4.71 billion, a price-to-earnings ratio of -10.67 and a beta of 1.49. The stock has a 50 day moving average price of $43.39 and a 200 day moving average price of $40.16.

Guardant Health (NASDAQ:GH - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.08. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The business had revenue of $203.47 million for the quarter, compared to the consensus estimate of $189.91 million. During the same quarter in the previous year, the firm earned ($0.46) earnings per share. The company's revenue for the quarter was up 20.8% on a year-over-year basis. Equities analysts forecast that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Insider Transactions at Guardant Health

In other news, CEO Amirali Talasaz sold 106,784 shares of the business's stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $49.01, for a total transaction of $5,233,483.84. Following the completion of the sale, the chief executive officer now directly owns 2,202,672 shares of the company's stock, valued at approximately $107,952,954.72. The trade was a 4.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last quarter, insiders have sold 107,132 shares of company stock valued at $5,248,393. 6.10% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on GH shares. Guggenheim reiterated a "buy" rating and issued a $56.00 price target on shares of Guardant Health in a research note on Monday, February 24th. Canaccord Genuity Group raised their price objective on shares of Guardant Health from $60.00 to $65.00 and gave the stock a "buy" rating in a report on Thursday, May 1st. Barclays raised their price objective on shares of Guardant Health from $55.00 to $60.00 and gave the stock an "overweight" rating in a report on Thursday, May 1st. Stephens reissued an "overweight" rating and issued a $55.00 price objective on shares of Guardant Health in a report on Wednesday, March 26th. Finally, Stifel Nicolaus raised their price objective on shares of Guardant Health from $53.00 to $60.00 and gave the stock a "buy" rating in a report on Thursday, May 1st. Twenty-one analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $52.32.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.